Poorer survival in obese colorectal cancer patients possibly linked to lower chemotherapy doses

Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021. Further findings showed that cumulative relative chemotherapy dose was associated with survival so may explain the poorer survival that has been seen in obese patients receiving adjuvant chemotherapy for colorectal cancer.